16.Breast Cancer Treatment for Premenopausal Women (Posted: 01/17/2006) - In this trial, premenopausal women with endocrine-responsive breast cancer will receive the drug triptorelin to suppress the function of their ovaries (induction of menopause) and long-term anti-estrogen therapy with either exemestane (an aromatase inhibitor), to inhibit the production of estrogen outside the ovaries, or tamoxifen, to block the growth-promoting effects of any estrogen that might be produced. Researchers hope to determine which anti-estrogen treatment will help premenopausal women whose ovarian function is being suppressed survive longer without a recurrence of their cancer. 17.Allogeneic Stem Cell Transplantation for Metastatic Breast Cancer (Posted: 11/22/2005) - In this study, researchers are investigating whether allogeneic stem cell transplantation (ASCT) followed by the infusion of donor Th2/Tc2 cells--a type of T lymphocyte that is able to suppress graft-versus-host disease--can be safely used to treat patients with metastatic breast cancer. 18.Adjuvant Breast Cancer Therapy for Premenopausal Women (Posted: 10/11/2005) - In this trial, researchers will study three treatment groups of premenopausal women with endocrine-responsive breast cancer to see which treatment regimen provides the greatest benefits for this population. 19.Targeted Combination Therapy for Advanced Solid Tumors (Posted: 07/19/2005) - In this study, researchers are assessing the safety and combined effectiveness of bevacizumab and a second drug called sorafenib. Both bevacizumab and sorafenib inhibit the formation of blood vessels to tumors and may act synergistically when combined. 20.Therapy for Postmenopausal Women with Metastatic Breast Cancer (Posted: 05/10/2005) - In this phase III trial, researchers are comparing the effectiveness of anastrozole alone or in combination with fulvestrant as first-line therapy in treating postmenopausal women who have hormone-sensitive, metastatic breast cancer.
